- AnaptysBio Inc (NASDAQ:ANAB) announced topline data from a Phase 1 trial of ANB032, an anti-BTLA agonist antibody.
- Topline data demonstrated favorable safety, tolerability, and rapid and sustained pharmacokinetics and pharmacodynamic profile, supporting the advancement of ANB032 into subsequent patient trials.
- ANB032 was generally well-tolerated, and no dose-limiting toxicities were observed.
- The Company said that ANB032 demonstrated rapid and sustained target engagement on T cells and B cells. Reduction of cell surface BTLA expression and the shedding of a portion of the cell surface BTLA as soluble BTLA was observed.
- AnaptysBio has a strategic portfolio review ongoing while continuing to execute on the development of its three antibody programs:
- Imsidolimab topline data from the GEMINI-1 Phase 3 trial in generalized pustular psoriasis and HARP Phase 2 trial in hidradenitis suppurativa is anticipated in Q4 of 2023 and Q3 of 2022, respectively.
- Related: AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne.
- Rosnilimab topline data from the AZURE Phase 2 trial in moderate-to-severe alopecia areata is anticipated in 1H of 2023
- ANB032 IND filing of Phase 2 trial is anticipated in 2H of 2022.
- Price Action: ANAB shares closed at $22.50 on Wednesday.
